Loading candles…
Dr. Reddy's Laboratories Ltd is a pharmaceutical company operating in the pharmaceutical industry with a presence in over 83 countries globally, including the United States, India, and emerging markets. The company offers a portfolio of products and services comprising active pharmaceutical ingredients (APIs), custom pharmaceutical services (CPS), generics, biosimilars, and differentiated formulations. Its operations are organized into key segments such as Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others, which include proprietary products. Dr. Reddy's focuses on providing affordable and innovative medicines worldwide. No information is available regarding its incorporation year, founders, key management, subsidiaries, notable projects, or stock exchange listings.
This page is a live market overview for DR. REDDY S LABORATORIES (DRREDDY) on the NSE. As a listed security, DR. REDDY S LABORATORIES is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for DRREDDY before placing trades on tick2trade.
As of the latest feed, DRREDDY last traded at ₹1,172 on NSE, up ₹1 (0.09%) from the previous close of ₹1,171. Today's session range is ₹1,162.1 – ₹1,172, against a 52-week band of ₹1,101 – ₹1,414.9. Traded volume today stands at 10.72L shares.
The overview consolidates an interactive price chart with multiple time ranges, a near-the-money option chain snapshot, recent market headlines, upcoming corporate events for DRREDDY in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether DRREDDY is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for DR. REDDY S LABORATORIES before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in DRREDDY. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated DRREDDY option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Unaudited Results - Q1-FY26 | To consider the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ending on June 30, 2026 | 22 Jul 2026 |
| Dividend | To recommend final dividend, if any, for the Financial year 2025-26 | 12 May 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 12 May 2026 |
| Results - Q4 & FY26 | To consider and approve the financial results for the quarter and year ending March 31, 2026 | 12 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 21 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 24 Oct 2025 |
| Unaudited Results - Q1-FY25 | To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ending on June 30, 2025 | 23 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters | 9 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.